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Abstract
The consumption of a diet rich in certain ﬂavonoids, including the ﬂavanol sub-class, has been associated with a reduced risk
for vascular disease. We evaluated the effects of the regular consumption (14d) of a ﬂavanol-containing milk chocolate
(FCMC) or cocoa butter chocolate (CBC) on variables related to vascular disease risk, oxidative stress and physical activity.
Twenty-eight free-living, young (18–20 years old) male soccer players consumed daily 105g of FCMC (168mg of ﬂavanols)
or CBC (,5mg of ﬂavanols), as part of their normal diet. The consumption of FCMC was signiﬁcantly associated with a
decrease in diastolic blood pressure (25mmHg), mean blood pressure (25mmHg), plasma cholesterol (211%), LDL-
cholesterol (215%), malondialdehyde (212%), urate (211%) and lactate dehydrogenase (LDH) activity (211%), and an
increase in vitamin E/cholesterol (þ12%). No relevant changes in these variables were associated with CBC consumption. No
changes in the plasma levels of (2)-epicatechin were observed following analysis of fasting blood samples. In conclusion,
FCMC consumption was associated with changes in several variables often associated with cardiovascular health and oxidant
stress.The presence of signiﬁcant quantities of ﬂavanols in FCMC is likely to have beenone of the contributing factorsto these
results.
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Introduction
Increasing effort is being given to the identiﬁcation
of dietary factors that can delay the onset or
progression of numerous age-related diseases
(Sunde 2001). While essential nutrients are being
widely studied in this regard, there is also interest in
the evaluation of “non-essential” nutrients that have
positive health effects. To a signiﬁcant extent, this
interest has been fueled by epidemiological studies,
which suggest that diets rich in plant foods are
associated with a reduced risk for vascular disease
(Ness and Powles 1997, Bazzano et al. 2002), and
possibly, some cancers (Steinmetz and Potter 1996).
Flavonoids are plant-derived compounds that
may have multiple beneﬁcial health effects (Hollman
2001, Nijveldt et al. 2001, Knekt et al. 2002).
The consumption of a diet rich in ﬂavonoids has
been associated with a reduced risk for vascular
disease (Kris-Etherton and Keen, 2002). While the
inverse association between the risk for vascular
disease and dietary ﬂavonoids intake does not prove
causality, an increasing amount of experimental data
pertaining to certain ﬂavonoids lends support to this
association (Middleton et al. 2000).
Cocoa is an example of food that can be a rich
dietary source of ﬂavonoids (Lazarus et al. 1999,
Arts et al. 1999). High concentrations of ﬂavonoids
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ﬂavanol monomers (2)-epicatechin (epicatechin)
and (þ)-catechin (catechin) along with the procya-
nidins (oligomers of the monomeric ﬂavanol base
units) (Adamson et al. 1999). Other potentially rich
dietary sources of ﬂavanols include tea, wine, grape
juice, apples, peanuts and certain nuts, although
growing conditions, post-harvest handling and
manufacture can have a signiﬁcant inﬂuence on the
ﬂavanol concentration of ﬁnished food products
(Haslam 1989).
The antioxidant properties of certain ﬂavonoids
have been the focus of considerable attention with
respect to the hypothesis that ﬂavonoids can reduce
the risk for certain oxidant stress-related diseases.
The antioxidant actions of the cocoa ﬂavanols
(epicatechin and catechin) and procyanidins have
been studied in vitro. For example, they have been
shown to inhibit the rate of LDL-, plasma- and
liposome-oxidation (Lotito and Fraga 1998, Lotito
and Fraga 2000, Lotito et al. 2000, Pearson et al.
2001). Observations recorded following acute con-
sumption of cocoa or chocolate rich in ﬂavanols have
been consistent with in vitro studies suggesting that
relatively high intake of dietary ﬂavanols can result in
an augmentation of the body’s oxidative defense
system over a short time period (Rein et al. 2000,
Wang et al. 2000, Osakabe et al. 2001, Wan et al.
2001). Perhaps, related to any potential modulation
of oxidant defense are the observations suggesting
that certain ﬂavanol-rich foods may improve biologi-
cal markers more speciﬁcally related to cardiovascular
health, including some that are potentially related to
blood pressure homeostasis (Diebolt et al. 2001).
While the above reports are encouraging, more
information is needed regarding the effects of
ﬂavanols on oxidative defense mechanisms and
other determinants of vascular health.
In this study we evaluated the effects of the regular
consumption (14d) of a ﬂavanol-containing milk
chocolate (FCMC) in comparison with a cocoa butter
(white) chocolate (CBC) prepared confectionery
containing negligible amount of ﬂavanols on several
parameters relating to cardiovascular health and
oxidant defense. The obtained results showed that
several health parameters, including blood pressure,
LDL- and total-cholesterol, and glucose levels
decreased after the intake of FCMC. These changes
were not observed when the same individuals
consumed isocaloric amounts of CBC. The consump-
tion of FCMC was also associated with a reduction in
plasma level of a lipid oxidation product. Considering
the relevance of the blood pressure reducing effect
observed after the FCMC consumption, and the ACE
inhibition exerted by ﬂavanols (Actis-Goretta et al.
2003), the results of this study induce to further
research on the vascular health beneﬁts of ﬂavanols
and related oligomers.
Subjects and methods
Subjects and dietary study design
Twenty-eight healthy, free-living, non-smoking
young male adults with no history of heart disease
or hemostatic disorders participated in this study was
carried out between October and November, 2000
(Table I). All the subjects were active soccer players
who were trained at least twice a week, and reported
that they had trained at such periodicity at least for
the past two years. All of the subjects played in at
least one 90-min-match per week in the Argentine
Football Association league before and during the
study period. The participants gave written informed
consent prior to their participation in the study.
During the initial 14-d period, 14 out of the 28
subjects were selected at random to consume FCMC
i nt h ef o r mo f1 0 5 go f“ M & M ’ s ” w chocolate
confectionery (Mars Incorporated, Recife, Brazil).
The other 14 subjects were given 105g of CBC. At the
end of this 14-d period, the two groups were crossed
over and subjects consumed the other confectionery
for another 14d. The subjects were free to consume
the confectionery at any time during the day. FCMC
and CBC were provided in 105g-coded bags (1-d
dose) for 7-d periods. Participants were instructed to
abstain from vitamin supplements and ﬂavonoid-rich
beverages, including alcohol, for at least 12h prior to
blood collection.
The nutrient composition of the two confectionery
products is shown in Table I. By analysis, 105g of
FCMC provided 168mg of ﬂavanols, of which
approximately 39mg (134mmol) were the epicatechin
and catechin, and, approximately, 126mg were higher
molecular weight procyanidins. CBC contained levels
of ﬂavanols under 5mg per 105g.
Subjects were fasted at least 8h prior to blood
collection. Venous blood (20ml) was obtained
between 08:00 and 09:00h, and collected in: (a)
three 10-ml plastic tubes containing K3EDTA,
potassium oxalate-sodium ﬂuoride, or sodium heparin
as anticoagulant, depending on the determination to
be performed and (b) one 5-ml glass tube to obtain
serum. Blood in the plastic tubes was subjected to low-
speed centrifugation (1500g at 48C for 10min), and
plasma was collected and stored at 2208C until
analyzed. Blood in the glass tubes was allowed to
coagulate at room temperature for 60min, and then
Table I. Baseline variables determined in the 28 subjects.
Variable Value
Weight (kg) 74 ^ 1
BMI (kgm
22) 24.1 ^ 0.2
Age (y) 18 ^ 1
Hematocrit 44.0 ^ 0.1
C. G. Fraga et al. 12serum was collected using a plastic pipette. Cardiac
frequency and blood pressure were determined
immediately before each blood draw using an
automatic inﬂation blood pressure monitor (Omron
HEM-712C, Omron Healthcare, Vernon Hills, IL).
Immediately after the blood draw, the subjects
performed a multistage 20min shuttle run
test to evaluate maximal VO2,a sa ni n d e xo f
physical performance.
Clinical determinations
Plasma triglycerides, total-, LDL- and HDL-chole-
sterol, urate, and creatinine kinase (CK) determi-
nations were carried out using commercial kits from
Wiener Lab., Rosario, Argentina. Lactate was
determined spectrophotometrically using an enzy-
matic kit (Randox Laboratories, Ltd., Crumlin, UK).
Glucose, blood proteins, and the activity of lactate
dehydrogenase (LDH), glutamyl pyruvate transferase
(GPT), and glutamyl ornithyl transferase (GOT) were
determined in a clinical laboratory using current
bioassays.
Malondialdehyde determination
Malondiadehyde (MDA) was assayed using frozen
heparinized plasma as described (Templar et al.
1999). Essentially, the separation of MDA was carried
out in an automated Perkin Elmer HPLC (pump ISS-
250, autosampler ISS 200) using a Waters 486 UV–
Vis detector set at 532nm. Chromatography was
driven by PE Nelson chromatography software that
allowed for data collection and analysis. The analytical
column was a reverse phase Supelco Hypersil ODS
column ð100 £ 4:6 £ 3mmÞ: The elution buffer was
65:35 (VV
21)5 0 m MK H 2PO4ZKOH (pH
7.0):methanol.
Oxo
8dG determination
The extent of blood DNA oxidation was evaluated
by quantifying the amount of 8-oxo-20-deoxyguano-
sine (oxo
8dG), an oxidized DNA base that occurs in
vivo. DNA from blood cells were isolated following
Nakae et al. (1995). After DNA hydrolysis, the
measurement of oxo
8dG and dG were carried out by
isocratic HPLC with coulometric (guard cell þ 400
mV, E1 þ 100mV; E2 þ 350mV) (Coulochem II
detector, ESA Inc., Bedford, MA) and UV (254nm)
detections (Helbock et al. 1998). A Supelcosil
LC-18DB column ð150 £ 4:6 £ 3mmÞ was used,
and the mobile phase consisted of 6:94 (VV
21)
50mM sodium acetate (pH 5.5):methanol. Solu-
tions of oxo
8dG and 20-deoxyguanosine prepared in
1mM deferoxamine, 20mM sodium acetate buffer,
pH 5.0, were used as standards.
Plasma antioxidant activity determination
Plasma antioxidant activity was determined as total
relative antioxidant potency (TRAP) as described
previously (Lissi et al. 1995) with minor modiﬁ-
cations. Plasma samples (5–10ml) were assayed for
their ability to inhibit the chemiluminescence pro-
duced by a mixture of 3ml of 5.4mgml
21 of 2,20-azo-
bis(amidinopropane) in 50mM sodium phosphate,
pH 7.4, and 10mlo f1 m g m l
21 luminol in NaOH
0.1Eql
21. The chemiluminescence was measured in a
liquid scintillation counter (Wallac 1410, Wallac Oy,
Turku, Finland). The TRAP value was calculated as
the lag time before an increase in the chemilumines-
cence was observed. This lag time is proportional to
the cumulative amount of antioxidants present in the
sample (Lissi et al. 1995). A reference lag time was
obtained by using a known amount of Trolox
(6-hydroxy-2, 5, 7, 8-tetramethoxychroman-2-carbo-
xylic acid) (Aldrich Chem. Co, Milwaukee, WI).
Lipid soluble antioxidant determination
Vitamin E (a-tocopherol), lycopene, b-carotene and
ubiquinol-10 (coenzyme Q-10) were determined by
HPLC with amperometric detection (Motchnik et al.
1994). The analysis was performed starting from 50ml
of frozen heparinized plasma. The amperometric
detector used was a BAS LC-4C 8 (Bioanalytical
Systems Inc., West Lafayette, IN) set at þ0.6Vand the
analytical column a reverse phase Supelcosil LC-8DB
columnð33 £ 4:6 £ 3mmÞ:Themobilephaseconsisted
of 98:2 (VV
21)2 0m ML i C l O 4:methanol.
Epicatechin and catechin determination
A 200ml aliquot of heparinized plasma was mixedwith
20ml of a solution containing 0.2gml
21 ascorbic acid,
1mgml
21 EDTA, and 20ml of beta-glucuronidase
suspension (about 2000 units of glucuronidase activity
and 80 units of sulfatase activity), and vortexed for
30s. Following a 45min-incubation at 378C, the
samples were treated as reported (Rein et al. 2000),
and epicatechin and catechin determined by HPLC
with coulometric detection using a reverse phase
Alltech Alltima C-18 column ð150 £ 4:6 £ 3mmÞ: The
mobile phase consisted of 30:70 (VV
21)5 0 m M
sodium acetate (pH 5.5):methanol. The coulometric
detector was an ESA Coulochem II (ESA Inc.,
Bedford, MA) equipped with an analytical cell, ESA
5111, set at þ0.8mV.
Statistical analysis
Results in the text and tables are expressed as
mean ^ SEM. Changes between the baseline (day 0)
and day 14 were examined by paired t test. Regression
analysis was used to compare associations between the
Flavanol-rich chocolate improves oxidant stress 13variables. Statistical signiﬁcance was assessed at the
5% level. Analysis was performed using routines
available in Statview for Windows v 5.0.1. (SAS
Institute Inc., Cary, NC).
Results
Participant characteristics are shown in Table II, and
there were no signiﬁcant differences in the analyzed
variables between the two groups. Twenty-seven of the
28 enrolled subjects completed the study. All of the
subjects reported that they consumed the appropriate
amount of product throughout the study period. None
of the subjects reported adverse effects and/or changes
in their athletic performance related to the con-
fectionery consumption. All of the subjects main-
tained their weight during the 28-d test period study.
Neither epicatechin nor catechin was detected in the
plasma samples through the study.
The results observed in several variables associated
with cardiovascular health are shown in Table III.
Relative to baseline values, diastolic and mean blood
pressure, blood levels of total cholesterol, LDL-
cholesterol and glucose were lower in the subjects after
they consumed FCMC for 14d as compared with
baseline values. No differences were observed in
the same variables determined before and after the
consumption of CBC (Table III).
The effects of the dietary treatments on oxidative
stress variables are shown in Table IV. Relative to
baseline values, plasma levels of malondialdehyde were
decreased by 12% after the 14-d of FCMC intake,
relativetobaselinevaluesðp , 0:001Þ:Incontrast,after
the 14-d period of CBC intake, plasma malondialde-
hyde levels were increased 10% ðp , 0:05Þ: Plasma
vitamin E (a-tocopherol) levels were not inﬂuenced by
the diets. However, the vitamin E/cholesterol and
vitamin E/LDL ratios were increased by 12% ðp ,
0:01Þ and 14% ðp , 0:03Þ; respectively, after FCMC
consumption. No changes were observed in vitamin E
levels and vitamin E/cholesterol and vitamin E/LDL
ratios after CBC consumption. Plasma b-carotene
concentrations were 13% lower after the intake of CBC
ðp , 0:05Þ: Plasma urate levels after 14d on FCMC
were 11% lower than baseline values ðp ¼ 0:05Þ: The
other oxidative stress markers assessed in this study
(blood levels of oxo
8dG and plasma TRAP, lycopene,
and coenzyme Q-10 concentrations) were not inﬂu-
enced by the consumption of FCMC or CBC.
The effects of the chocolate consumption on select
physiological exercise variables are shown in Table V.
Relative to baseline values, after CBC consumption,
blood lactate values decreased by 22% ðp , 0:03Þ:
Plasma LDH activity was signiﬁcantly lower (11%)
than baseline activity in the subjects after the intake of
FCMC ðp , 0:001Þ: There was no effect of the dietary
treatments on plasma GOT, GPT, or CK activities or
in maximal VO2.
Discussion
We observed that daily intake of FCMC for 14d
favorably inﬂuenced several variables associated with
cardiovascular health and oxidant defense in well-
conditioned young men. The contribution of FCMC
to the total caloric intake of the subjects was about
11% considering an average total caloric intake of
about 4000kCal per day. Presumably, the addition of
Table III. Changes in physiological variables observed after 14 days of FCMC or CBC consumption.
FCMC CBC
Variable Baseline Day 14 p Baseline Day 14 p
Cardiac frequency (min
21)5 9 ^ 26 1 ^ 2 0.40 62 ^ 25 7 ^ 2 0.05
Systolic blood pressure (mmHg) 123 ^ 3 117 ^ 2 0.06 123 ^ 3 121 ^ 2 0.54
Diastolic blood pressure (mmHg) 72 ^ 26 7 ^ 2 0.01 71 ^ 27 0 ^ 2 0.74
Mean blood pressure (mmHg) 89 ^ 28 4 ^ 2 0.008 88 ^ 28 7 ^ 2 0.64
Cholesterol (mgdl
21) 167 ^ 6 149 ^ 4 0.009 156 ^ 5 157 ^ 5 0.69
LDL-cholesterol (mgdl
21) 107 ^ 59 1 ^ 4 0.02 101 ^ 59 6 ^ 4 0.47
HDL-cholesterol (mgdl
21)3 5 ^ 23 3 ^ 1 0.20 33 ^ 13 5 ^ 2 0.36
LDL/HDL 3.2 ^ 0.2 2.8 ^ 0.1 0.14 3.1 ^ 0.2 2.9 ^ 0.2 0.37
Triglycerides (mgdl
21)9 2 ^ 12 81 ^ 5 0.30 86 ^ 59 2 ^ 11 0.48
Values are mean ^ SEM. p is obtained from the comparison of day 14 and day 0 values (paired t-test). There were no signiﬁcant differences
between baseline values for any of the variables determined.
Table II. Total nutrient composition of FCMC and CBC.
Nutrient FCMC (%) CBC (%)
Fat 21.3 21.6
Lactose 4.4 8.0
Sucrose 54.5 60.2
Fiber 2.5 nd
Ash 1.6 1.5
Caffeine 0.017 nd
Theobromine 0.17 nd
Moisture 1.7 1.3
Protein 4.3 4.1
Minerals 0.6 0.5
Cholesterol 0.014 0.014
Flavanols 0.16 nd
Data provided by Mars, Incorporated.
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the consumption of other foods as body weight during
the 28-d test period was unaffected.
High blood pressure is a risk factor for numerous
diseases (stroke, cardiovascular disease) while
reductions in blood pressure, even within normal
range may be beneﬁcial. FCMC consumption was
associated with a modest, but signiﬁcant, reduction in
blood pressure. This effect was not an acute effect as
shown by the results from our laboratory in a group of
young adults (21–23 years) (unpublished). The
change in blood pressure was not observed when the
subjects consumed the CBC. A similar study carried
out in aged people, showed a similar effect of the
consumption of chocolate on blood pressure (Taubert
et al. 2003). Flavonoid-rich foods have demonstrated
the potential to inﬂuence endothelial function in
humans (Duffy et al. 2001, Heiss et al. 2003), and to
modulate nitric oxide synthesis and/or bioavailability
in and around the vascular bed (Karim et al. 2000,
Freedman et al. 2001). Given that the main difference
between the two products consumed in this study was
the ﬂavanol content of FCMC, it is therefore, possible
that the favorable blood pressure changes recorded in
this study were ultimately mediated through an action
of the ﬂavanols, or their metabolites. But, it is also
possible to consider as an alternative mechanism,
the inhibition of the angiotensin converting enzyme
(ACE) activity. In this regard, we have shown that
ﬂavanols extracted from cocoa, including epicatechin
and the dimer and hexamer procyanidin fractions,
inhibit ACE activity in vitro (Actis-Goretta et al.
2003). Furthermore, it was reported that the intake of
pomegranate juice, which is rich in ﬂavonoids,
lowered blood pressure in a group of hypertensive
patients (Aviram and Dornfeld 2001) and that the oral
administration of wine polyphenols decreased blood
pressure in rats (Diebolt et al. 2001). More research
on this potential interaction needs to be undertaken to
conﬁrm the plausibility of these vascular actions in
vivo.
FCMC consumption was also associated with a
decrease in blood levels of total-cholesterol and
LDL-cholesterol, but not with signiﬁcant changes in
HDL-cholesterol and total plasma triglyceride levels.
These observations are consistent with the ﬁndings of
a study of Japanese women that showed an inverse
correlation between ﬂavonoid intake and plasma
LDL-cholesterol (Arai et al. 2000). We also noted
that the above ﬁndings are in contrast with those of
Wan et al. (2001), who observed no changes in total
and LDL-cholesterol, and a subtle increase in the level
of HDL-cholesterol (4%), after the consumption of a
mixture of dark chocolate and cocoa powder.
Table V. Changes in physiological variables observed after 14 days of FCMC or CBC consumption.
FCMC CBC
Variable Baseline Day 14 p Baseline Day 14 p
Lactate 9.7 ^ 59 1 ^ 4 0.55 12.9 ^ 0.9 10.0 ^ 0.6 0.03
Lactate dehydrogenase (Ul
21) 397 ^ 14 354 ^ 12 0.001 373 ^ 11 362 ^ 10 0.26
GOT (Ul
21) 25.1 ^ 3.1 23.1 ^ 1.4 0.48 22.6 ^ 1.1 25.0 ^ 3.0 0.41
GPT (Ul
21) 23.9 ^ 2.8 23.9 ^ 2.5 0.93 21.5 ^ 1.5 24.7 ^ 3.0 0.12
Creatinine kinase (Ul
21) 232 ^ 22 223 ^ 19 0.56 203 ^ 20 235 ^ 20 0.12
VO2 (mlkg
21min
21) 55.2 ^ 0.8 55.2 ^ 0.7 0.73 54.7 ^ 0.6 57.3 ^ 0.9 0.10
Values are mean ^ SEM. p is obtained from the comparison of day 14 and day 0 values, using paired t-test. There were no signiﬁcant
differences between baseline values for any of the variables determined.
Table IV. Changes in oxidative stress variables observed after 14 days of FCMC or CBC consumption.
FCMC CBC
Variable Day 0 Day 14 p Day 0 Day 14 p
Malondialdehyde (nM) 85 ^ 37 5 ^ 3 0.001 80 ^ 38 8 ^ 2 0.04
Oxo
8dG (bases per 10
5dG) 1.8 ^ 0.1 1.8 ^ 0.2 0.95 1.6 ^ 0.3 1.8 ^ 0.2 0.39
TRAP (s) 325 ^ 27 282 ^ 13 0.20 304 ^ 19 322 ^ 24 0.72
Vitamin E (mM) 28.4 ^ 1.5 28.5 ^ 1.1 0.83 27.8 ^ 1.3 28.8 ^ 1.3 0.28
Vitamin E/cholesterol 0.17 ^ 0.01 0.19 ^ 0.01 0.01 0.18 ^ 0.01 0.19 ^ 0.01 0.91
Vitamin E/LDL 0.28 ^ 0.02 0.32 ^ 0.01 0.02 0.29 ^ 0.02 0.31 ^ 0.02 0.40
b-Carotene (mM) 0.40 ^ 0.09 0.38 ^ 0.05 0.86 0.39 ^ 0.06 0.34 ^ 0.05 0.04
Lycopene (mM) 0.46 ^ 0.05 0.47 ^ 0.05 0.54 0.46 ^ 0.05 0.46 ^ 0.05 0.98
Coenzyme Q-10 (mM) 0.42 ^ 0.03 0.40 ^ 0.03 0.74 0.41 ^ 0.03 0.43 ^ 0.04 0.54
Urate (M) 0.28 ^ 0.01 0.25 ^ 0.02 0.05 0.25 ^ 0.02 0.26 ^ 0.02 0.54
Values are mean ^ SEM. p is obtained from the comparison of day 14 and day 0 values (paired t-test). There were no signiﬁcant differences
between baseline values for any of the variables determined.
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massive amount of literature indicating that the
ingestion of cocoa butter, or chocolate containing
cocoa butter, is not associated with changes in any
blood cholesterol parameters (Wan et al. 2001,
Mathur et al. 2002). This reinforces our observation
that CBC consumption had a neutral effect on blood
cholesterol, but is not in line with the decrease in total-
and LDL-cholesterol after FCMC consumption that
we report here. From these results we speculate that
the high content of ﬂavanols and procyanidins in the
chocolate used in our study could be responsible for
the decrease in total- and LDL-cholesterol.
With respect to oxidative stress, plasma malondi-
aldehyde levels were lower after 14d of FCMC
consumption compared to baseline. This result agrees
with previous reports of an inverse association
between plasma thiobarbituric acid reactive sub-
stances (TBARS) concentrations and plasma epi-
catechin concentrations in subjects given different
amounts of ﬂavanol-rich chocolate (Rein et al. 2000,
Wang et al. 2000). Similarly, decreased rates of ex-vivo
LDL oxidation have been reported in individuals after
the consumption of ﬂavanol-rich chocolate (Osakabe
et al. 2001, Wan et al. 2001). The other studied
marker of oxidative stress oxo
8dG as well as the
oxidant defenses (TRAP, vitamin E, b-carotene,
lycopene, and ubiquinol-10) followed in this study
were unaffected by the dietary treatments. It is worth
considering that the observed higher ratios of vitamin
E to cholesterol and to LDL after the consumption of
the FCMC are suggestive of improved antioxidant
protection of plasma cholesterol and LDL. However,
it should be considered that this relative increase could
be associated with the decrease in cholesterol
concentration. A potential relationship between
oxidative stress and blood pressure can not be
disregarded. This may be related to a direct
scavenging effect by the ﬂavanols and procyanidins,
and/or with the regulation of the oxidants and/or nitric
oxide steady state in vascular associated cells (Diebolt
et al. 2001, Leikert et al. 2002).
It is interesting to note that we did not detect
epicatechin or procyanidins in the plasma after the
14d consumption of FCMC. Similar results were
reported by Osakabe et al. (2001), although in that
study an increased urinary excretion of epicatechin
was observed 1 and 2 weeks after cocoa consumption.
The absence of epicatechin and/or procyanidins was
expected considering that we drew the blood after a
8h-fast, and the majority of absorbed epicatechin and
dimer are cleared from the blood by that time (Rein
et al. 2000, Holt et al. 2002). Absence of epicatechin
in the plasma could be responsible for the absence of
an increase in the total plasma antioxidant activity
(TRAP) in the fasted blood samples when subjects
were consuming FCMC. Thus, while epicatechin is
an example of a nutrient that is only transiently
detected in blood, the potential health beneﬁts of
ﬂavanols suggested both in vitro and following
consumption by humans emphasizes the need for
further study to determine if other tissues might take
up these bioactive compounds. In this regard, we have
observed that ﬂavanols, especially, the dimer fraction
can inﬂuence cell signaling in Jurkat cells (Mackenzie
et al. 2004). Thus, additional research will also be
needed to determine how individual cells within these
tissues might accumulate and/or metabolize the
ﬂavanols.
In conclusion, we observed several changes in
markers associated with cardiovascular health and
oxidant defense following consumption of FCMC by
physically active young men. Particularly striking were
the observations that FCMC favorably modulated
both blood pressure and blood cholesterol levels as
compared to CBC consumption. Given, that we
previously reported that select ﬂavanols inhibit ACE
in vitro (Actis-Goretta et al. 2003), this may therefore
represent another mechanism associated with cardio-
vascular health that ﬂavanols can target following
consumption and absorption. Finally, some para-
meters related to oxidant defense were favorably
modulated, and this is consistent with the well-
documented strong antioxidant potential of ﬂavanols.
Taken together, the results from this study provide
further supporting evidence for the hypothesis
that the regular consumption of ﬂavanol-rich foods
can positively contribute to cardiovascular health.
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